Table 1

Characteristics of subjects in the HATFF study at entry

Age (years)45 ± 13
Sex (male/female)8/21
BMI (kg/m2)30.0 ± 3.8
Overweight/obese18/11
FPG (mmol/L)3.93 ± 0.57
A1C (mmol/mol)36.2 ± 4.3
A1C (%)5.5 ± 0.7
Prediabetes (no/yes)20/9
GFR (mL/min)97 ± 17
Systolic BP (mmHg)133 ± 12
Diastolic BP (mmHg)83 ± 10
Hypertension (no/yes)18/11
  • Data are mean ± SD or number of each classification (class 1/class 2) unless otherwise indicated; n = 29. Hypertension was defined as systolic blood pressure (BP) ≥140 mmHg or diastolic blood pressure ≥90 mmHg on 4 occasions. Thirty-two subjects were recruited at the University Hospitals of Coventry and Warwickshire National Health Service Trust in the period May–July 2014; the last participant left the study December 2014. At prescreening, assessments made were 2-h plasma glucose in an OGTT and A1C, aspartate transaminase, alanine transaminase, plasma triglycerides, and plasma creatinine (for estimated glomerular filtration rate [GFR]). One participant was withdrawn from the study for diverging from the protocol, and 2 dropped out: 1 while on placebo and 1 on treatment. The 2 participants who dropped out stated personal reasons related to interfering duties and therefore difficulties attending the scheduled follow-up appointments. None of the participants reported any relevant side effects (nausea, loss of appetite, gastrointestinal side effects, or other symptoms). Study data were analyzed per protocol (n = 29).